用于支持治疗、感染控制和公共卫生的碳青霉烯酶机制检测：临床实验室的作用
Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.
作者信息
Blosser Sara J, Bhatnagar Amelia S, Bollinger Susan, Giffen Samantha R
机构信息
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Goldbelt Professional Services, LLC, Chesapeake, VA, USA.
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
出版信息
Clin Lab Med. 2025 Mar;45(1):51-61. doi: 10.1016/j.cll.2024.10.006. Epub 2024 Nov 16.
Abstract
Carbapenemase mechanism testing in carbapenem-resistant Enterobacterales is essential for informing patient treatment, infection prevention, and control. By highlighting the clinical and infection control imperative for this testing, addressing current barriers, and delineating future needs, we set the stage and advocate for routine carbapenemase mechanism testing in all clinical laboratories in the United States.
摘要
对耐碳青霉烯类肠杆菌科细菌进行碳青霉烯酶机制检测对于指导患者治疗、预防和控制感染至关重要。通过强调该检测在临床和感染控制方面的紧迫性、解决当前存在的障碍并描述未来需求，我们奠定了基础并倡导在美国所有临床实验室开展常规碳青霉烯酶机制检测。
相似文献
1
Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.用于支持治疗、感染控制和公共卫生的碳青霉烯酶机制检测：临床实验室的作用
Clin Lab Med. 2025 Mar;45(1):51-61. doi: 10.1016/j.cll.2024.10.006. Epub 2024 Nov 16.
2
Analysis of clinical characteristics of patients with coronavirus disease 2019 based on a superior carbapenem-resistant Enterobacterales identification strategy.基于一种高级耐碳青霉烯类肠杆菌鉴定策略的2019冠状病毒病患者临床特征分析
Medicine (Baltimore). 2025 Jun 27;104(26):e43046. doi: 10.1097/MD.0000000000043046.
3
Improved diagnostic stewardship in carbapenem-resistant gene detection helps in early initiation of targeted therapy.改善耐碳青霉烯类基因检测中的诊断管理有助于早期启动靶向治疗。
J Med Microbiol. 2025 Jun;74(6). doi: 10.1099/jmm.0.002029.
4
An update on carbapenem-resistant Enterobacterales: A prospective study from Western India.耐碳青霉烯类肠杆菌科细菌的最新情况：来自印度西部的一项前瞻性研究。
J Postgrad Med. 2025 Apr 1;71(2):61-67. doi: 10.4103/jpgm.jpgm_558_24. Epub 2025 Jun 9.
5
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
6
Carbapenem-resistant Enterobacterales among patients with bloodstream infections in South Africa: Consolidated surveillance data, 2015-2021.南非血流感染患者中耐碳青霉烯类肠杆菌科细菌：2015 - 2021年综合监测数据
PLoS One. 2025 Jul 2;20(7):e0324262. doi: 10.1371/journal.pone.0324262. eCollection 2025.
7
Laboratory detection of carbapenemases among Gram-negative organisms.革兰氏阴性菌中碳青霉烯酶的实验室检测
Clin Microbiol Rev. 2024 Dec 10;37(4):e0005422. doi: 10.1128/cmr.00054-22. Epub 2024 Nov 15.
8
An Automated Assay for Carbapenemase Detection in Enterobacterales: a Real-World Performance.
Clin Lab. 2025 Aug 1;71(8). doi: 10.7754/Clin.Lab.2025.250150.
9
[Consensus on the diagnosis and treatment of carbapenemase-producing enterobacterial infections].[产碳青霉烯酶肠杆菌感染诊断和治疗的共识]
Medicina (B Aires). 2025;85(4):822-845.
10
Molecular epidemiology and clinical characteristics of carbapenem-resistant bloodstream and pneumonia isolates.耐碳青霉烯类血流感染和肺炎分离株的分子流行病学及临床特征
Microbiol Spectr. 2025 Aug 5;13(8):e0063125. doi: 10.1128/spectrum.00631-25. Epub 2025 Jul 9.
本文引用的文献
1
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.全球卫生组织优先细菌病原体中碳青霉烯类和难以治疗的耐药性趋势：2018-2022 年 ATLAS 监测计划。
J Glob Antimicrob Resist. 2024 Jun;37:168-175. doi: 10.1016/j.jgar.2024.03.020. Epub 2024 Apr 10.
2
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
3
Evaluation of the NG-Test CARBA 5 Lateral Flow Assay with an IMP-27-Producing Morganella morganii and Other .评价产 IMP-27 摩根摩根菌的 NG-Test CARBA 5 侧向流检测试剂盒及其他…
Microbiol Spectr. 2023 Jun 15;11(3):e0079323. doi: 10.1128/spectrum.00793-23. Epub 2023 May 18.
4
Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant .定向碳青霉烯酶检测不再仅仅针对肠杆菌科：扩大碳青霉烯酶检测至碳青霉烯类耐药的成本、劳动力和工作流程评估。
Emerg Microbes Infect. 2023 Dec;12(1):2179344. doi: 10.1080/22221751.2023.2179344.
5
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.表型、基因型和断点：评估针对 OXA-48 的β-内酰胺/β-内酰胺酶抑制剂组合。
J Antimicrob Chemother. 2023 Mar 2;78(3):636-645. doi: 10.1093/jac/dkac425.
6
Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales.产碳青霉烯酶肺炎克雷伯菌和头孢他啶-阿维巴坦快速分子检测对碳青霉烯类耐药肠杆菌科菌血症患者结局的影响。
Clin Infect Dis. 2022 Dec 19;75(12):2066-2075. doi: 10.1093/cid/ciac354.
7
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
8
Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019.检测和鉴定目标性碳青霉烯类耐药的卫生保健相关性威胁：来自抗生素耐药实验室网络的研究结果，2017 年至 2019 年。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0110521. doi: 10.1128/AAC.01105-21. Epub 2021 Sep 27.
9
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.新型碳青霉烯酶抑制剂：为β-内酰胺类药物开辟道路。
Int J Mol Sci. 2020 Dec 6;21(23):9308. doi: 10.3390/ijms21239308.
10
Antibiotic Susceptibility of NDM-Producing Collected in the United States in 2017 and 2018.2017年和2018年在美国收集的产NDM菌株的抗生素敏感性
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00499-20.
Zotero 插件